QUADRANT CAPITAL GROUP LLC - CONMED CORP ownership

CONMED CORP's ticker is CNMD and the CUSIP is 207410101. A total of 151 filers reported holding CONMED CORP in Q2 2017. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
QUADRANT CAPITAL GROUP LLC ownership history of CONMED CORP
ValueSharesWeighting
Q3 2023$114,062
-38.2%
1,131
-16.7%
0.01%
-38.9%
Q2 2023$184,539
+52.9%
1,358
+16.9%
0.02%
+38.5%
Q1 2023$120,686
+33.0%
1,162
+13.5%
0.01%
+30.0%
Q4 2022$90,767
+53.8%
1,024
+38.9%
0.01%
+25.0%
Q3 2022$59,000
+391.7%
737
+499.2%
0.01%
+300.0%
Q2 2022$12,000
-40.0%
123
-5.4%
0.00%0.0%
Q1 2022$20,000
+122.2%
130
+97.0%
0.00%
+100.0%
Q4 2021$9,000
-10.0%
66
-9.6%
0.00%0.0%
Q3 2021$10,000
+100.0%
73
+92.1%
0.00%0.0%
Q2 2021$5,0000.0%380.0%0.00%0.0%
Q1 2021$5,000
+25.0%
380.0%0.00%0.0%
Q4 2020$4,000
+100.0%
38
+52.0%
0.00%
Q3 2020$2,0000.0%250.0%0.00%
Q2 2020$2,000
+100.0%
25
-16.7%
0.00%
Q1 2020$1,000
-85.7%
30
-60.0%
0.00%
-100.0%
Q4 2019$7,000
+250.0%
75
+200.0%
0.00%
Q3 2019$2,0000.0%250.0%0.00%
Q2 2019$2,000
-96.7%
25
-96.7%
0.00%
-100.0%
Q1 2019$61,000
+6000.0%
747
+2888.0%
0.01%
Q4 2018$1,0000.0%250.0%0.00%
Q3 2018$1,0000.0%250.0%0.00%
Q2 2018$1,0000.0%250.0%0.00%
Q1 2018$1,0000.0%250.0%0.00%
Q4 2017$1,0000.0%250.0%0.00%
Q3 2017$1,0000.0%250.0%0.00%
Q2 2017$1,0000.0%250.0%0.00%
Q1 2017$1,0000.0%250.0%0.00%
-100.0%
Q4 2016$1,000250.00%
Other shareholders
CONMED CORP shareholders Q2 2017
NameSharesValueWeighting ↓
Endurant Capital Management LP 41,984$4,234,0863.80%
Ranger Investment Management 334,874$33,772,0432.24%
SECTORAL ASSET MANAGEMENT INC 114,000$11,496,9002.24%
EARNEST PARTNERS LLC 2,265,092$228,434,5281.32%
MOUNTAIN PACIFIC INVESTMENT ADVISERS INC/ID 144,376$14,560,3201.01%
EPIQ PARTNERS, LLC 10,463$1,055,1940.80%
Hood River Capital Management LLC 236,127$23,813,4080.76%
Heritage Wealth Partners, LLC 3,375$340,3690.73%
Champlain Investment Partners, LLC 943,260$95,127,7710.62%
WESTWOOD HOLDINGS GROUP INC 559,157$56,3910.53%
View complete list of CONMED CORP shareholders